13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001618205
Total reported value
$213.8M
$213.8M
60 檔
25.8%
During the Q2 2024 filing period, Birchview Capital, LP (CIK: 0001618205) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $213.8M across 60 reported positions.
During Q2 2024, Birchview Capital, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 26.42% | -2.56% | -2.19% | |
| 2 | ✓ | Biodesix Inc | Stock-Other | 8.04% | +0.65% | +6.50% | |
| 3 | ELUT | Elutia Inc | Stock-Other | 7.11% | -0.02% | -6.25% | |
| 4 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 5.37% | +0.10% | -45.31% | |
| 5 | SILKUSD | Silk Road Medical Inc | Stock-Other | 3.95% | — | — | |
| 6 | PRTA | Prothena Corporation plc | Stock-Other | 3.88% | -0.42% | +20.05% | |
| 7 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 3.76% | -0.15% | — | |
| 8 | OVV | Ovintiv Inc | Stock-Energy | 3.21% | -0.98% | -11.88% | |
| 9 | UTHR | United Therapeutics CORP | Stock-Healthcare | 2.94% | -0.38% | -9.09% | |
| 10 | HROW | Harrow Inc | Stock-Other | 2.90% | — | — | |
| 11 | STOK | Stoke Therapeutics Inc | Stock-Other | 2.62% | -1.16% | — | |
| 12 | PHR | Phreesia Inc | Stock-Other | 2.25% | -0.07% | EXIT | |
| 13 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 2.22% | +1.25% | +48.00% | |
| 14 | QDELUSD | Quidelortho CORP | Stock-Other | 2.08% | -0.04% | +3.71% | |
| 15 | MASI* | Masimo CORP | Stock-Other | 1.78% | — | — | |
| 16 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 1.71% | -0.13% | — | |
| 17 | ETRNUSD | Equitrans Midstream CORP | Stock-Other | 1.60% | — | — | |
| 18 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.54% | -0.09% | — | |
| 19 | AXGN | Axogen Inc | Stock-Other | 1.32% | — | +13.87% | |
| 20 | DCGO | Docgo Inc | Stock-Other | 1.31% | — | — | |
| 21 | ALKS | Alkermes plc | Stock-Healthcare | 1.11% | +0.22% | — | |
| 22 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.93% | +0.28% | — | |
| 23 | ATEC | Alphatec Holdings Inc | Stock-Other | 0.85% | — | — | |
| 24 | CSTL | Castle Biosciences Inc | Stock-Other | 0.68% | -0.04% | +142.86% | |
| 25 | XOM | Exxon Mobil CORP | Stock-Energy | 0.62% | — | — | |
| 26 | PGNY | Progyny Inc | Stock-Other | 0.58% | — | — | |
| 27 | TXG | 10x Genomics Inc-class A | Stock-Other | 0.54% | — | — | |
| 28 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.52% | — | — | |
| 29 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.50% | -0.65% | EXIT | |
| 30 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.50% | +0.07% | — | |
| 31 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.50% | -0.32% | EXIT | |
| 32 | HALO | Halozyme Therapeutics Inc | Stock-Healthcare | 0.48% | +0.85% | — | |
| 33 | CHRS | Coherus Oncology Inc | Stock-Other | 0.43% | — | — | |
| 34 | KPTIEUR | Karyopharm Therapeutics Inc | Stock-Other | 0.38% | -0.07% | — | |
| 35 | ARVN | Arvinas Inc | Stock-Other | 0.37% | — | — | |
| 36 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.37% | — | — | |
| 37 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.36% | -0.11% | — | |
| 38 | ✓ | Accelerate Diagnostics Inc | Stock-Other | 0.35% | — | — | |
| 39 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.35% | — | — | |
| 40 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.32% | +0.01% | -20.36% | |
| 41 | NVCR | NovoCure Limited | Stock-Healthcare | 0.32% | -1.26% | EXIT | |
| 42 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.30% | +0.11% | — | |
| 43 | KROS | Keros Therapeutics Inc | Stock-Other | 0.30% | — | — | |
| 44 | ✓ | Stock-Other | 0.28% | — | -3.11% | ||
| 45 | AM6 | Amicus Therapeutics Inc | Stock-Other | 0.26% | — | — | |
| 46 | BHVN | Biohaven Ltd. | Stock-Other | 0.24% | — | — | |
| 47 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.23% | — | +100.00% | |
| 48 | XNCR | Xencor Inc | Stock-Other | 0.22% | — | — | |
| 49 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.18% | — | — | |
| 50 | GTHXEUR | G1 Therapeutics Inc | Stock-Other | 0.17% | — | — |
According to official SEC Form 13F filings, Birchview Capital, LP reported a total U.S. public equity portfolio value of $213.8M across 60 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BMY, BIODESIX INC, ELUT) accounted for 25.8% of total reported equity market value during Q2 2024.
During Q2 2024, Birchview Capital, LP's top holdings by market value included BMY (26.4%)、BIODESIX INC (8.0%)、ELUT (7.1%). The largest single position, BMY, represented 26.4% of total portfolio value.
In Q2 2024, Birchview Capital, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.